. . "~33%"@en . . . . . . "4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide"@en . . . . . "Laszlo Kovacs, Csaba Szabo, Erika Molnarne, Adrienne Kovacsne-Mezei, Claude Singer, Judith Aronhime, \"Method of making dorzolamide hydrochloride.\" U.S. Patent US20060155132, issued July 13, 2006."@en . . . . . . . . "Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest"@en . . . "Dorzolamide"@en . "(4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide"@en . "(4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide"@en . . . . . . . . . "Dorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed."@en . . . . "(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide"@en . "Dorzolamida"@en . . . . . "4 months"@en . . . . . . . . . . . . . . . . . "approved"@en . . "Dorzolamide"@en . "Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine."@en . "Dorzolamidum"@en . "120279-96-1"@en . "Humans and other mammals"@en . . . "Dorzolamide is a carbonic anhydrase (CA) inhibitor. It is used in ophthalmic solutions (Trusopt) to lower intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension."@en . . . "# Plummer CE, MacKay EO, Gelatt KN: Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs. Vet Ophthalmol. 2006 Jul-Aug;9(4):245-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16771760 # Grover S, Apushkin MA, Fishman GA: Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006 May;141(5):850-8. Epub 2006 Mar 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16546110 # Almeida GC Jr, Faria e Souza SJ: Effect of topical dorzolamide on rabbit central corneal thickness. Braz J Med Biol Res. 2006 Feb;39(2):277-81. Epub 2006 Feb 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16470316 # Martens-Lobenhoffer J, Banditt P: Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet. 2002;41(3):197-205. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11929320 # Balfour JA, Wilde MI: Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging. 1997 May;10(5):384-403. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9143858 # Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G: Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Pharm Biotechnol. 1998;11:555-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9760696"@en . . . . . "For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy)."@en . . "4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide"@en . . . . . . "4S,6S-Dorzolamide"@en . . . . "Dorzolamid"@en . " "@en . . . .